Aion Medicines, a subsidiary of Exavir Therapeutics, announced the presentation of preclinical data for AM-710, the company's ultra-long-acting small molecule GLP1R agonist, at the ObesityWeek ...
Than Powell Than Powell, CBO, Longeveron On track for top-line trial results in the third quarter of 2026 from pivotal Phase ...
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, ...
New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC[*] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback